Aristotle University Of Thessaloniki (AUTH)
Ανάπτυξη mRNA μορίων στη θεραπευτική προσέγγιση μεταβολικών/μονογονιδιακών νοσημάτων με την αξιοποίηση της τεχνολογίας των πεπτιδίων μεταγωγτής (PTDs/CPPs)
Abstract
dc:descriptionThe in vitro transcribed (IVT)-mRNA resembles the natural mRNA and its successful intracellular delivery allows the transient expression of the corresponding exogenous protein by the cells' own translational machinery. The strongest advantage of IVT-mRNA technology is that mRNA molecules do not interfere with the host genome. Its successful application relies on the development of safe and efficient delivery, which remains challenging. In this doctoral dissertation, an innovative methodology for combining the technology of Protein Transduction Domains (PTDs) with IVT-mRNA was developed as a delivery platform, forming the PTD-IVT-mRNA. PTD technology employs short peptides, able to transduce almost all cellular membranes, carrying intracellularly a variety of «cargoes» from micro-molecules to macromolecules. The produced, capped and poly-(A) tailed, IVT- mRNAs can be combined with a selected PTD, thus offering a delivery platform for any possible therapeutic IVT-mRNA of interest and as an alternative approach to Protein Replacement Therapy (PRT). To evaluate the efficacy of the transduction capacity and translation of each protein, the PTD- IVT-mRNA platform was selected to be studied in two disease models, β-thalassemia and a primary mitochondrial disorder, the fatal infantile cardioencephalomyopathy and cytochrome c oxidase (COX) deficiency, due to mutations in the SCO2 gene. Initially, several plasmid vectors were designed and cloned, to produce the templates of the in vitro transcription, which carried the coding sequence of either the Green Fluorescence Protein (GFP) gene, the β-globin gene or the SCO2. Upstream and downstream of the respective coding sequence, the 5′-UTR (murine β-globin) and 3′-UTR (human β- globin) were coned, respectively, for greater stability of the produced IVT-mRNA produced. The IVT- mRNA was then conjugated to the selected PTD and PTD-IVT-mRNA analysis by NMR spectroscopy confirmed the successful conjugation. In addition, during the stability experiments, the PTD-IVT- mRNA showed significantly increased resistance and relatively no degradation, after incubation, under adverse conditions, in the presence of harmful RNases, compared to the naked IVT-mRNA. In the preliminary experiments, for the initial evaluation of the innovative PTD-IVT-mRNA platform, it was applied in human K-562 cell line model, using the IVT-mRNA of GFP, as a marker of IVT-mRNA transduction and protein expression. Then, transduction experiments with the PTD-IVT-mRNA followed, of both β-globin and SCO2, in K-562 cells, and the intracellular IVT-mRNA transduction and kinetic expression of each protein were studied, with encouraging results. Subsequently, the evaluation of the PTD-IVT-mRNA platform was performed on bone marrow cells, derived from three β-thalassemia patients, as well as in primary fibroblasts, derived from a patient with SCO2/COX deficiency. Interestingly, PTD-IVT-mRNA also exhibits encouraging rates of intracellular IVT- mRNA transduction and high expression efficacy. Moreover, complementation of the phenotype was also demonstrated by increasing COX function, in the case of intracellular transduction of PTD-IVT- mRNA of SCO2, into fibroblasts, from a patient with SCO2/COX deficiency. The results showed a high potential for intracellular transduction of PTD-IVT-mRNA, as it addresses problems of stability, transduction, and translation of IVT-mRNAs, suggesting that the PTD-IVT-mRNA is a potential candidate for Protein Replacement Therapy, both for monogenic and mitochondrial-metabolic disorders.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Miliotou, Androulla
- Μηλιώτου, Ανδρούλλα
Subjects
dc:subject × 15- In vitro μεταγραφόμενο mRNA
- Πεπτίδια μεταγωγής
- Μονογονιδιακά νοσήματα
- Μεταβολικά νοσήματα
- Β-θαλασσαιμία
- Sco2
- In vitro transcribed mRNA
- Protein transduction domain
- Monogenic diseases
- Metabolic disorders
- Beta-thalassemia
- Ιατρική Βιοτεχνολογία
- Ιατρική και Επιστήμες Υγείας
- Medical Biotechnology
- Medical and Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/48870